Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2011 May 1;21(9):2759-63. doi: 10.1016/j.bmcl.2010.10.132. Epub 2010 Oct 31.

Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.

Author information

1
Sandwich Chemistry, World Wide Medicinal Chemistry, Pfizer, Ramsgate Road, Sandwich CT13 9NJ, UK. lyn.jones@pfizer.com

Abstract

This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.

PMID:
21075627
DOI:
10.1016/j.bmcl.2010.10.132
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center